Viewing entries tagged
icahn school of medicine at mount sinai

Xofigo (Radium-223): An Overview

2 Comments

Xofigo (Radium-223): An Overview

Radium-223 is used to treat bone metastases, a common problem for men living with metastatic hormone resistant prostate cancer (MHRPC), affecting up to 90% of these patients. The development of a drug called radium-223 (brand name: Xofigo) is a substantial innovation, not only because it causes less toxicity compared to its predecessors, but also because it prolongs life.

2 Comments